https://orcid.org/0000-0003-1974-7844
References
- Cohen PR. Sweet’s syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.
- Cohen PR, Kurzrock R. Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42(10):761–778.
- Sweet RB. An acute febrile neutrophtlic dermatosts. Br J Dermatol. 1964;76(8–9):349–356.
- Kazmi SM, Pemmaraju N, Patel KP, et al. Characteristics of Sweet’s syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(6):358–363.
- McMahon CM, Perl AE. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia. Expert Rev Clin Pharmacol. 2019;12(9):841–849.
- Cohen PR, Kurzrock R. Sweet’s syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol. 2000;18(3):265–282.
- Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet’s syndrome: review of the world literature. J Clin Oncol Off J Am Soc Clin Oncol. 1988;6(12):1887–1897.
- Aractingi S, Mallet V, Pinquier L, et al. Neutrophilic dermatoses during granulocytopenia. Arch Dermatol. 1995;131(10):1141–1145.
- Cohen PR, Almeida L, Kurzrock R. Acute febrile neutrophilic dermatosis. Am Fam Physician. 1989;39(3):199–204.
- Su WP, Liu HN. Diagnostic criteria for Sweet’s syndrome. Cutis. 1986;37(3):167–174.
- Sweet’s syndrome without granulocytosis - Probert, MD - 1998 - international journal of dermatology - Wiley online library. [cited 2019 Nov 17]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-4362.1998.00270.x
- Fathi AT, Le L, Hasserjian RP, et al. FLT3 inhibitor-induced neutrophilic dermatosis. Blood. 2013;122(2):239–242.
- Varadarajan N, Boni A, Elder DE, et al. FLT3 inhibitor-associated neutrophilic dermatoses. JAMA Dermatol. 2016;152(4):480–482.
- Ozcelik T, Ozkocaman V, Ali R, et al. Sweet’s syndrome: dilemma in febrile neutropenic patient with acute myeloid leukemia. Leuk Res. 2006;30(11):1466–1468.